Mendus Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Mendus wird ein jährliches Gewinn- und Umsatzwachstum von 92.4% bzw. 89.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 95.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 2.3% betragen.

Wichtige Informationen

92.4%

Wachstumsrate der Gewinne

95.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.7%
Wachstumsrate der Einnahmen	89.9%
Zukünftige Eigenkapitalrendite	2.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate

Aug 31

Gewinn- und Umsatzwachstumsprognosen

OM:IMMU - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	62	N/A	N/A	N/A	1
12/31/2025	100	-31	61	61	2
12/31/2024	3	-122	-72	-72	1
9/30/2024	7	-138	-73	-70	N/A
6/30/2024	32	-141	-178	-175	N/A
3/31/2024	28	-107	-163	-160	N/A
12/31/2023	28	-102	-165	-163	N/A
9/30/2023	27	-104	-189	-187	N/A
6/30/2023	27	-116	-115	-114	N/A
3/31/2023	1	-141	-123	-119	N/A
12/31/2022	3	-139	-122	-109	N/A
9/30/2022	2	-128	-124	-114	N/A
6/30/2022	2	-117	-126	-114	N/A
3/31/2022	2	-119	-123	-114	N/A
12/31/2021	0	-133	-139	-138	N/A
9/30/2021	N/A	-148	-130	-129	N/A
6/30/2021	N/A	-138	-112	-111	N/A
3/31/2021	0	-119	-91	-90	N/A
12/31/2020	N/A	-89	-57	-57	N/A
9/30/2020	16	3	11	13	N/A
6/30/2020	16	-11	-7	-5	N/A
3/31/2020	17	-31	-22	-21	N/A
12/31/2019	17	-48	-58	-58	N/A
9/30/2019	0	-118	-114	-114	N/A
6/30/2019	0	-112	-102	-102	N/A
3/31/2019	N/A	-98	-89	-89	N/A
12/31/2018	N/A	-98	-105	-105	N/A
9/30/2018	N/A	-90	-88	-88	N/A
6/30/2018	N/A	-89	N/A	-89	N/A
3/31/2018	N/A	-88	N/A	-94	N/A
12/31/2017	N/A	-80	N/A	-46	N/A
9/30/2017	N/A	-86	N/A	-76	N/A
6/30/2017	N/A	-77	N/A	-75	N/A
3/31/2017	N/A	-72	N/A	-68	N/A
12/31/2016	N/A	-61	N/A	-59	N/A
9/30/2016	N/A	-48	N/A	-51	N/A
6/30/2016	N/A	-44	N/A	-40	N/A
3/31/2016	N/A	-37	N/A	-33	N/A
12/31/2015	N/A	-38	N/A	-35	N/A
9/30/2015	N/A	-37	N/A	-37	N/A
6/30/2015	N/A	-36	N/A	-40	N/A
3/31/2015	N/A	-33	N/A	-33	N/A
12/31/2014	N/A	-28	N/A	-24	N/A
9/30/2014	N/A	-21	N/A	-18	N/A
6/30/2014	N/A	-16	N/A	-9	N/A
3/31/2014	N/A	-13	N/A	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMMU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMMU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMMU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMMUDie Einnahmen des Unternehmens (89.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-0% pro Jahr).

Hohe Wachstumseinnahmen: IMMUDie Einnahmen des Unternehmens (89.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IMMUDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (2.3%).

Mendus Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 36% to kr29.00

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates increase by 172%

Consensus revenue estimates decrease by 63%

Consensus revenue estimates increase by 172%

Recent updates

Price target increased by 36% to kr29.00

New major risk - Revenue size

Mendus AB (publ), Annual General Meeting, May 09, 2025

Mendus AB (publ) to Report Fiscal Year 2024 Final Results on Apr 18, 2025

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New minor risk - Profitability

No longer forecast to breakeven

Now 20% overvalued

Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate

Now 24% overvalued

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Independent Director exercised options to buy kr460k worth of stock.

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

Chief Executive Officer recently bought kr120k worth of stock

We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate

Mendus AB (Publ) Announces Clinical Pipeline Update

Consensus revenue estimates increase by 172%

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Consensus revenue estimates decrease by 63%

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates increase by 172%

Mendus AB (publ), Annual General Meeting, May 17, 2024

New major risk - Share price stability

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Mendus (STO:IMMU) Is Making Moderate Use Of Debt

Price target decreased by 23% to kr5.00

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Is Mendus (STO:IMMU) Using Debt Sensibly?

Price target decreased to kr5.30

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Is Mendus (STO:IMMU) Using Debt Sensibly?

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Chief Financial Officer recently bought kr216k worth of stock

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr97k worth of stock

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Is Immunicum (STO:IMMU) Using Too Much Debt?

Chief Executive Officer recently bought kr252k worth of stock

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought kr2.4m worth of stock